Physician profile
Stefanie Vaimakis
NPI 1396802633
$46,775.48
in general payments reported to CMS, 2019-2025
20 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $4,593 · 2021: $221 · 2022: $142 · 2023: $31.49 · 2024: $1,412 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,101 · Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,101.10 |
| Food and Beverage | $704.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $43,015.61 | 2019-2020 | |
| Medical Device Business Services, INC. | $1,304.97 | 2024 | Linx Reflux Management System, Echelon Flex |
| W. L. Gore & Associates, INC. | $659.61 | 2019 | |
| Novo Nordisk INC | $638.53 | 2019-2025 | Wegovy |
| Endo Pharmaceuticals INC. | $266.67 | 2019-2022 | |
| Kerecis Limited | $186.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vivus LLC | $130.76 | 2019-2022 | |
| Ethicon US, LLC | $91.90 | 2019-2024 | Linx Reflux Management System |
| Ambu INC. | $86.49 | 2025 | |
| Eisai INC. | $66.35 | 2019 | |
| Currax Pharmaceuticals LLC | $58.25 | 2020-2025 | Contrave |
| Recordati_rare_diseases_inc. | $56.16 | 2024-2025 | Isturisa, Signifor Lar |
| Teleflex LLC | $50.21 | 2020-2025 | Titan Sgs Bailout Chuck |
| Nalpropion Pharmaceuticals LLC | $40.86 | 2019 | |
| Lilly USA, LLC | $38.21 | 2023-2024 | Zepbound |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $28.17 | 2022 | |
| Davol INC. | $18.36 | 2019 | |
| Intra-Sana Laboratories | $13.50 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Redhill Biopharma INC. | $13.05 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Vaimakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.